Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2002-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-001-0247-1PMID 11845256PMCID PMC11032933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

  2001influential reference
• Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

  2001influential reference
• Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis

  2000cited by this paper
• Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

  2000influential reference
• Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.

  2000influential reference
• Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

  2000influential reference
• Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

  2000influential reference
• Risk factors for side effects during first infusion of rituximab—definition of a low risk group

  2000cited by this paper
• Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.

  2000cited by this paper
• Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.

  2000influential reference
• Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

  2000cited by this paper
• Complement activation in heart diseases. Role of oxidants.

  2000cited by this paper
• Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma

  2000influential reference
• Use of rituximab, the new FDA-approved antibody.

  1998cited by this paper
• Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

  1998cited by this paper
• Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody

  1998cited by this paper
• Methods for detecting and quantifying apoptosis.

  1998cited by this paper
• Apoptosis detection: an overview.

  1998cited by this paper
• A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody.

  1997cited by this paper
• Engagement of CD20 suppresses apoptosis in germinal center B cells

  1995cited by this paper
• Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article.

  1994cited by this paper
• Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies

  1987cited by this paper
• Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

  1986cited by this paper
• The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.

  1985cited by this paper
• The interaction of murine IgG subclass proteins with human monocyte Fc receptors.

  1985cited by this paper
• Characterization of a human B lymphocyte-specific antigen.

  1980cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper

• The complement system in clinical oncology: Applications, limitations and challenges.

  2024cites this paper
• Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody‐Drug Conjugates in Preclinical Models

  2024cites this paper
• Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy

  2022cites this paper
• Development of an SPR-based binding assay for characterization of anti-CD20 antibodies to CD20 expressed on extracellular vesicles.

  2022cites this paper
• Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease.

  2022cites this paper
• Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis

  2021cites this paper
• Immunotherapy of cancer

  2021cites this paper
• Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis–related interstitial lung diseases: a retrospective, observational cohort study

  2021cites this paper
• The Role of B Cells in Adult and Paediatric Liver Injury

  2021cites this paper
• Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects

  2020cites this paper
• Conventional and Nonconventional Approaches to Site-Specific Targeting of Nanotherapeutics in Some Infectious Diseases and Metabolic Disorders

  2020cites this paper
• Macromolecular approach for targeted radioimmunotherapy in non-Hodgkin's lymphoma.

  2019cites this paper
• Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.

  2019cites this paper
• Hybrid Imaging and Radionuclide Therapy in Hemato-oncology

  2019cites this paper
• Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti‐CD20 Antibody for the Treatment of Non‐Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  2018cites this paper
• Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases

  2018cites this paper
• Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future

  2017cites this paper
• Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells

  2017cites this paper
• CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.

  2017cites this paper
• Effectiveness of rituximab in nephrotic syndrome treatment

  2017cites this paper
• Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation

  2016cites this paper
• Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease

  2016cites this paper
• New perspectives on complement mediated immunotherapy.

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Radionuclide Therapy of Lymphomas

  2016cites this paper
• Therapeutic Effects of Intravenous Immunoglobulin, Platelet Transfusion and B Cell Depletion on Murine Immune Thrombocytopenia (ITP)

  2016cites this paper
• A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.

  2016cites this paper
• The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

  2015cites this paper
• Rituximab for treatment of rheumatoid hyperviscosity syndrome: Pulmonary arterial hypertension and post- partum cardiomyopathy cases

  2015cites this paper
• Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro

  2015cites this paper
• Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.

  2015cites this paper
• Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.

  2015influential citation
• Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non‐Hodgkin's Lymphoma

  2014cites this paper
• Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”)

  2014cites this paper
• The role of complement in tumor growth.

  2014cites this paper
• Apoptotic B cells: their interactions with macrophages and modulation by rituximab

  2014influential citation
• Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.

  2014cites this paper
• B cells participate in tolerance and autoimmunity through cytokine production

  2014cites this paper
• Tumor Microenvironment and Cellular Stress

  2014cites this paper
• Itolizumab (Alzumab), Mogamulizumab (Poteligeo), and Tositumomab (Bexxar)

  2014cites this paper
• Ofatumumab (Arzerra®): a Next‐Generation Human Therapeutic CD20 Antibody with Potent Complement‐Dependent Cytotoxicity

  2014cites this paper
• Prediction of adverse events in patients receiving rapid rituximab infusion: validation of a predictive model.

  2014cites this paper
• Follow-up Data of 10 Patients With B-cell Non-Hodgkin Lymphoma With a CD20-negative Phenotypic Change After Rituximab-containing Therapy

  2013cites this paper
• Adverse events to monoclonal antibodies used for cancer therapy

  2013cites this paper
• Antibody-mediates inhibition of human C1s and the classical complement pathway.

  2013cites this paper
• Rituximab biosimilars

  2013cites this paper
• Acquired haemophilia treated successfully with rituximab in a patient with pemphigus vulgaris

  2013cites this paper
• segregation into lipid 'rafts' Complement-mediated lysis by anti-CD20 mAb correlates with

  2013cites this paper
• Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells

  2013cites this paper
• Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype

  2013cites this paper
• chronic lymphocytic leukemia Transient down-modulation of CD20 by rituximab in patients with

  2013cites this paper
• Monoclonal antibodies in neuroinflammatory diseases

  2013cites this paper
• Mechanisms of action of CD20 antibodies.

  2012cites this paper
• Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.

  2012cites this paper
• Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

  2012cites this paper
• Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions.

  2012cites this paper
• Mechanisms of action of CD 20 antibodies

  2012cites this paper
• Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

  2012cites this paper
• Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling

  2012cites this paper
• Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics.

  2012cites this paper
• Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.

  2012cites this paper
• Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.

  2012cites this paper
• Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells

  2012cites this paper
• Biophysical Considerations for Development of Antibody-Based Therapeutics

  2012cites this paper
• Implication de l'association CD20/CD40 dans la mort cellulaire induite via le CD20

  2012influential citation
• Expression and biological characterization of an anti-CD20 biosimilar candidate antibody

  2012cites this paper
• Review Article Mechanisms of action of CD20 antibodies

  2012cites this paper
• Radioimmunotherapy-based treatment of cancer

  2012cites this paper
• scFv Antibody: Principles and Clinical Application

  2012cites this paper
• Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.

  2011cites this paper
• Cancer radioimmunotherapy.

  2011cites this paper
• The Dock-and-Lock (DNL) Approach to Novel Bispecific Antibodies

  2011cites this paper
• Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.

  2011cites this paper
• Cell Death Signaling and Anticancer Therapy

  2011cites this paper
• Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’

  2011cites this paper
• The future of anti-CD 20 monoclonal antibodies : are we making progress ?

  2011cites this paper
• Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

  2011cites this paper
• not due to activation of complement depleting activity of type II anti-CD20 mAb is - Response: Superior B cell

  2011cites this paper
• The future of anti-CD20 monoclonal antibodies: are we making progress?

  2011cites this paper
• BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.

  2011cites this paper
• Radioimmunotherapy for CD20-positive B-cell non-Hodgkin's lymphoma

  2011cites this paper
• Characterisation of anti-glycan monoclonal antibodies

  2011influential citation
• Targeted Radionuclide Therapy

  2011cites this paper
• Monoclonal antibodies in hematological malignancies: past, present and future.

  2011cites this paper
• RADAR Commentary: Evolution and Current Status of Dosimetry in Nuclear Medicine

  2011cites this paper
• Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

  2011cites this paper
• Role of B Cells in Rheumatic Autoimmune Disease

  2010cites this paper
• and immune effector cellmediated B-cell cytotoxicity engineering of a new type II anti-CD20 antibody with enhanced direct Increasing the efficacy of CD20 antibody therapy through the

  2010cites this paper
• Practical considerations on the use of rituximab in autoimmune neurological disorders

  2010cites this paper
• Development of novel humanized anti‐CD20 antibodies based on affinity constant and epitope

  2010cites this paper
• I-131 tositumomab

  2010cites this paper
• Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum

  2010cites this paper
• The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis

  2010cites this paper
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

  2010cites this paper
• Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

  2009cites this paper
• Induced by OFA than by RTX Considerably Higher Levels of CDC Are Ofatumumab (OFA) or Rituximab (RTX): of B Cells Opsonized with Anti-CD20 mAbs Complement-Dependent Cytotoxicity (CDC) Binding of Submaximal C1q Promotes

  2009cites this paper
• Histological and immunophenotypic changes in 59 cases of B‐cell non‐Hodgkin's lymphoma after rituximab therapy

  2009cites this paper
• A review of the current use of rituximab in autoimmune diseases.

  2009cites this paper
• Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

  2009cites this paper
• Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap

  2009cites this paper